GSK secures rights to Syndivia’s ADC asset for prostate cancer
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
Novartis to Acquire Avidity Biosciences for US$12 Billion in Rare-Disease Push
Novartis to Acquire Avidity Biosciences Novartis will buy Avidity Biosciences for US$12 billion, gaining its RNA-based therapeutic platfor…
Park Hyatt Saigon Presents “Passion Week 2025” | Saigoneer
Park Hyatt Saigon Presents “Passion Week 2025” A Celebration of Culinary Mastery, Artistry & Cultural Excellence. Park Hyatt Saigon announ…
Palestinian Farmers Attacked During Olive Harvest
Palestinian Farmers Attacked During Olive Harvest Palestinian farmers harvesting olives in the occupied West Bank were assaulted by Israel…
Snapback Activation Not Economic Game-Changer
Snapback Activation Not Economic Game-Changer A new study by the Iranian Parliament’s research arm has assessed the legal, political and e…
Nearly 2,000 people attend community event
Nearly 2,000 People Attend Community Event Nearly 2,000 people attended Godmanchester's Apple Day at the Community Plant Nursery on Octobe…
Herefordshire couple told ‘no’ to solar panels on historic farmhouse
Herefordshire Couple Denied Solar Panels on Historic Farmhouse A government planning inspector has rejected a Herefordshire couple's appli…